Pulmonology · 2025
Feasibility of DNA and RNA preservation from EBUS-TBNA supernatant for molecular profiling in non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vaz Rodrigues Luís, Oliveira Joana, Ladeirinha Ana Filipa, Alarcão Ana, Taborda-Barata Luis, Cordovilla Rosa, Sousa Vitor
Аннотация
BACKGROUND: Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is used to diagnose and stage Non-Small Cell Lung Cancer (NSCLC), where the supernatant is discarded.
RESEARCH QUESTION: Can DNA/RNA extracted directly from formaldehyde-preserved EBUS-TBNA supernatant, provide sufficient and reliable molecular profiling in NSCLC?
STUDY DESIGN AND METHODS: This prospective study included patients with advanced NSCLC (stage III-IV) undergoing EBUS-TBNA to compare DNA/RNA quantification, NGS feasibility and molecular findings between the supernatant phase (Sp) and the cell pellet (Cp).
RESULTS: The median DNA and RNA concentrations were significantly higher in Sp than Cp, with Sp showing 29.9 ng/µL DNA and 52.12 ng/µL RNA versus 9.58 ng/µL and 13.6 ng/µL in Cp (Wilcoxon signed rank test, p = 0.012 and p = 0.005). MP in Cp identified 16 mutations (7 actionable), while Sp detected 19 mutations, including two additional actionable mutations. Concordance between Cp and Sp was 87%, with identical mutations in 13 cases and discrepancies in two cases.
CONCLUSIONS: Sp obtained from EBUS-TBNA is a rich source of tumour DNA and RNA, with high feasibility for NGS. There is strong concordance of NGS results between Cp and Sp, supporting Sp as a complementary/alternative source for molecular profiling in NSCLC, potentially reducing the need for additional biopsies.
RESEARCH QUESTION: Can DNA/RNA extracted directly from formaldehyde-preserved EBUS-TBNA supernatant, provide sufficient and reliable molecular profiling in NSCLC?
STUDY DESIGN AND METHODS: This prospective study included patients with advanced NSCLC (stage III-IV) undergoing EBUS-TBNA to compare DNA/RNA quantification, NGS feasibility and molecular findings between the supernatant phase (Sp) and the cell pellet (Cp).
RESULTS: The median DNA and RNA concentrations were significantly higher in Sp than Cp, with Sp showing 29.9 ng/µL DNA and 52.12 ng/µL RNA versus 9.58 ng/µL and 13.6 ng/µL in Cp (Wilcoxon signed rank test, p = 0.012 and p = 0.005). MP in Cp identified 16 mutations (7 actionable), while Sp detected 19 mutations, including two additional actionable mutations. Concordance between Cp and Sp was 87%, with identical mutations in 13 cases and discrepancies in two cases.
CONCLUSIONS: Sp obtained from EBUS-TBNA is a rich source of tumour DNA and RNA, with high feasibility for NGS. There is strong concordance of NGS results between Cp and Sp, supporting Sp as a complementary/alternative source for molecular profiling in NSCLC, potentially reducing the need for additional biopsies.